Flossbach Von Storch SE Decreases Stock Position in Stryker Co. (NYSE:SYK)

Flossbach Von Storch SE decreased its holdings in Stryker Co. (NYSE:SYK - Free Report) by 6.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 394,666 shares of the medical technology company's stock after selling 29,366 shares during the quarter. Flossbach Von Storch SE owned about 0.10% of Stryker worth $142,099,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dunhill Financial LLC lifted its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares during the period. Darwin Wealth Management LLC purchased a new position in Stryker in the third quarter valued at about $36,000. Activest Wealth Management acquired a new stake in shares of Stryker during the 4th quarter valued at approximately $36,000. Crews Bank & Trust purchased a new stake in shares of Stryker during the 4th quarter worth approximately $39,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker in the 3rd quarter worth approximately $42,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 1.0 %

Stryker stock traded down $3.82 during trading on Friday, hitting $382.59. The company's stock had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. The stock's fifty day moving average is $377.92 and its 200 day moving average is $368.21. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company posted $3.46 earnings per share. As a group, equities research analysts predict that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of several research reports. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a report on Thursday, January 30th. Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. The Goldman Sachs Group increased their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research note on Thursday, January 30th. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, Evercore ISI upped their price target on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of "Moderate Buy" and a consensus target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.